Executive Summary

Two converging trends define the coming decade in wound and skin infection care. First, resistance to the antibiotics medicine currently relies on, including the topical agents used on the vast majority of everyday skin and wound infections, is rising steadily and, in some jurisdictions, has already passed the point of routine clinical usefulness. Second, the only well-evidenced, broad-spectrum topical alternative with no confirmed resistance mechanism, high-MGO bioactive (Mānuka-type) honey, is produced almost entirely by wild, land-constrained harvest that cannot expand to meet even current demand, let alone the demand a genuine topical-antibiotic-replacement scenario would create.

This briefing sets out the evidence for both trends, places them on a shared timeline, and makes the case that meeting future demand requires abandoning small-scale, wild-harvest thinking in favour of deliberately engineered, industrial-scale apicultural permaculture. Plantations on the order of 250 hectares, designed around a two-phase nutrient/bioactive flowering cycle rather than a single wild species in a single remote region. David Munday’s granted patent portfolio is, on current evidence, the only intellectual property in existence directly claiming a method for producing bioactive honey at this scale, independent of any single geography.

The Antimicrobial Resistance Timeline

Antimicrobial resistance (AMR) is not a distant risk; it is a measured, worsening trend with a well-documented trajectory.

2019: 1.27M deaths directly caused by AMR; 4.95M deaths associated with it.

2030: WHO global-action-plan target year; economic loss estimated up to €3 trillion/year by this point.

2050: Up to 10M deaths/year projected, more than current annual cancer deaths, with cumulative losses in the tens of millions of lives from 2024 onward.

The World Health Organization classes AMR among the top ten global public health threats. Roughly 700,000–1.3 million deaths a year are already directly attributable to resistant infections, contributing to close to 5 million deaths annually; more than HIV, tuberculosis and malaria combined. Absent a change of course, WHO-aligned modelling puts the annual toll at up to 10 million deaths by 2050, which would make AMR a larger annual killer than cancer is today; a separate 2024 Lancet analysis projects over 39 million cumulative deaths from AMR between 2024 and 2050.

Topical Antibiotics Are Failing First

The resistance crisis is often framed around hospital-grade, systemic antibiotics, but the erosion is furthest advanced in the everyday topical antibiotics used for skin and wound infections. Precisely the use-case a bioactive honey plantation product is positioned to serve.

• New Zealand: community fusidic-acid resistance in Staphylococcus aureus rose from 17% (1999) to 28% (2015), among the highest rates recorded globally, alongside similar rises reported in the UK and Australia.
• Mupirocin, the other front-line topical agent, shows resistance among coagulase-negative staphylococci ranging from roughly 13% in Europe to nearly 39% in the United States, with resistance among hospitalised MRSA isolates reported as high as 65% in some settings.
• Clinicians now flag a second-order risk: resistance selected by topical use can co-select for resistance to unrelated, systemic antibiotics carried on the same mobile genetic elements; meaning overused topical treatment is accelerating resistance well beyond the skin.

The clinical guidance already reflects this: New Zealand’s own prescriber body (bpac.nz) has called the need to restrict topical antibiotic use “urgent,” and topical fusidic acid is not even licensed in the United States because of resistance concerns. There are, at present, very few approved topical antibiotic alternatives in the pipeline. Retapamulin (Altabax) is one of the only recent approvals, and it is active against methicillin-susceptible staphylococci only, offering no answer to MRSA.

Why Bioactive Honey Is Different

High-MGO bioactive honey is not simply “another antimicrobial” waiting to be defeated the same way. Laboratory transcriptomic work (Macquarie University / UTS, published in mSystems, 2020) found that honey acts on bacteria through many simultaneous, unrelated mechanisms at once: osmotic dehydration, hydrogen peroxide, acidity, polyphenol activity, disruption of the electron transport chain and membrane depolarisation, interference with quorum sensing, and induced DNA/oxidative damage, rather than a single molecular target the way conventional antibiotics do.

Researchers explicitly tested whether resistance could be induced in the laboratory using passaging conditions that reliably produce antibiotic resistance within days, and could not induce honey resistance under the same conditions. As the study’s authors put it, this multi-mechanism action “does not engender bacterial resistance.” Manuka-type honey has demonstrated effectiveness even against pathogens already resistant to conventional drugs, including ciprofloxacin-resistant Pseudomonas aeruginosa. No confirmed case of honey-resistant bacteria has been reported in the literature to date.

This is the scientific basis for treating bioactive honey not as a niche wellness product, but as a genuine, mechanistically distinct replacement class for topical antibiotics at the exact moment those antibiotics are failing.

The Supply Wall

The problem is not efficacy. It is production. Medical-grade, high-MGO bioactive honey today comes almost entirely from wild Leptospermum scoparium (Mānuka) harvest in remote regions of New Zealand and Australia, a supply model that is structurally incapable of scaling.

• A single hive yields only around 10–15 kg of high-grade honey in a good year; hives are helicoptered into remote “honey spots” because the highest-potency bloom grows on hard-to-reach terrain.
• The nectar-flow itself is finite: it “cannot be scaled up simply by adding more bees”. The land has a fixed carrying capacity that global demand does not respect, and overcrowding hives in one area causes colony starvation (“bee wars”).
• The result is chronic supply-demand imbalance and price volatility: wholesale prices for premium grades have risen 15–30% in a single year, with retail jars reported as high as several thousand dollars, even as reports also describe periodic gluts and beekeeper losses when quality grading disappoints; a boom-bust pattern typical of an unmanaged wild resource, not an industrial input.
• On the demand side, the global Mānuka honey market alone was valued near US$780M in 2023 (6.1% CAGR to 2034), medical-grade honey specifically is forecast to grow at roughly 13% CAGR, and the broader global wound care market, the immediate addressable market for a topical-antibiotic replacement, was valued at US$23.1B in 2024, projected to reach US$32.8B by 2033.

Every recall, shortage, or quality-control failure in the current supply chain, Medline’s 2023 TheraHoney recall and Integra’s more recent MediHoney recall among them, demonstrates the same underlying fragility: the entire medical-honey industry depends on a single, geographically narrow, non-scalable wild resource.

Think Big: 250-Hectare Apicultural Permaculture

Meeting a topical-antibiotic-replacement scale of demand, not a niche wellness market, but a genuine front-line clinical alternative, requires abandoning the wild-harvest model altogether and engineering bioactive honey production the way any other essential medical input is produced: deliberately, at industrial scale, in a controlled and repeatable environment.

The Monocrop Trap: Why “Just Plant More Bioactive Species” Does Not Work

The naive response to a supply shortage is to plant more of the bioactive species itself. More Leptospermum, at greater density, over a larger area. This fails on apicultural grounds, and the failure is well-documented: bees cannot sustain a colony on a bioactive-plant monocrop.

• Leptospermum pollen is characteristically low in protein. Colonies foraging a pure stand can gather the nectar but not the protein needed to rear brood, maintain glandular development, or make the return flight to the hive beyond a very short range, a constraint recorded in the granted patent specification itself.
• Peer-reviewed apicultural research confirms the general mechanism: honey bee immunocompetence, broodrearing, glandular development and colony survival all depend on adequate dietary protein and, under parasite or disease pressure, on pollen diversity specifically. Monofloral protein-poor diets measurably reduce colony health and lifespan (Alaux et al., 2010; Di Pasquale et al., 2013; and subsequent studies).
• In practice, commercial beekeepers already work around this by feeding manufactured protein substitutes or trucking hives out to alternative forage when working monofloral bioactive stands; an admission, from within the industry itself, that a bioactive monocrop alone cannot keep a colony alive at commercial scale.

A plantation designed as a bioactive monocrop is therefore self-defeating: it starves the very colonies it depends on, collapsing yield long before it reaches 250 hectares of productive scale. This is precisely why the patent claims a method built around paired nutrient and bioactive planting rather than a bioactive monocrop. The nutrient-species rings are not a decorative addition to the design, they are the condition that makes an industrial-scale bioactive plantation biologically possible at all.

David Munday’s granted patent portfolio claims exactly this: a method (not a species, and not a single location) for introducing insects and medicinal-honey-producing flora into a shared engineered environment to produce a wanted bioactive result. Central to the method is a two-phase flowering sequence across concentric plantation zones: an outer, then inward-cycling, sequence of nutrient-species flowering (building colony health and protein reserves) followed by bioactive-species flowering (yielding the high-MGO honey), repeated across the season. This solves the core biological constraint of monofloral Leptospermum harvest: that the bioactive species alone lacks the protein diversity bees need to stay healthy, while also producing two harvest events, and two revenue events, from one plantation per cycle.

At scale (plantations in the order of 250 hectares, replicable in any suitable climate) this converts bioactive honey from a scarce wild commodity into a planned agricultural output, in the same way managed forestry replaced reliance on old-growth timber, or plantation rubber replaced wild-harvested latex. Because the method is claimed independently of species and geography, it is deployable wherever climate allows: the granted jurisdictions alone (Australia, New Zealand, UK, Canada, three US patents, Hong Kong, India, South Africa) already span most of the world’s major wound-care manufacturing and consumption regions.

On the evidence reviewed for this briefing, no other granted patent claims a comparably scaled, geographyindependent method for engineered bioactive honey production. The combination of a real and worsening topicalantibiotic resistance crisis, a mechanistically resistance-proof alternative, a wild-harvest supply model that cannot scale, and a single granted method that can, is the case for treating this patent portfolio as infrastructure for a coming public-health need, not simply a honey-industry asset.

Appendix — Think Big: Illustrative Scale References

The following image was supplied as visual references for the scale of engineered circular/concentric agricultural layout under discussion. Large-format centre-pivot-style plantations, shown here for scale and layout inspiration rather than as literal plantation designs.

Sources

• WHO / Lancet Global Burden of Disease AMR forecasts (2024)
• UNRIC/WHO AMR campaign materials
• PMC systematic reviews on AMR mechanisms and mitigation (2023–2026)
• bpac.nz “Topical antibiotics: very few indications for use” and related NZ prescribing data
• PMC5786761 (topical antibiotic coselection study)
• mSystems 2020 honey mechanism-of-action study (Macquarie University/UTS)
• Allied Market Research and SkyQuest medical/functional honey market reports
• Straits Research global wound care market report (2024–2033)
• Bloomberg, The Grocer, and industry sources on Mānuka honey supply constraints and pricing.

This briefing synthesises third-party research and public market data; it does not constitute proof-of-concept or yield data for the patented method, which remains at development stage as disclosed in prior correspondence with prospective partners.